Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:I54's EV-to-EBITDA is ranked worse than 92.29% of 402
companies
in the Biotechnology industry
Industry Median: 13.91
vs FRA:I54: 104.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biocytogen Pharmaceuticals (Beijing) Co's PE Ratio (TTM) for today is calculated as:
Biocytogen Pharmaceuticals (Beijing) Co's share price for today is €6.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.107.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBITDA Chart
Biocytogen Pharmaceuticals (Beijing) Co Annual Data
FRA:I54 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biocytogen Pharmaceuticals (Beijing) Co EV-to-EBITDA vs Biotechnology Industry
Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is €5,854.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €56.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a EV-to-EBITDA of 104.03 as of Sep. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biocytogen Pharmaceuticals (Beijing) Co. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #371 out of 402 companies in the Biotechnology industry, placing it in the top 92.3%.
Is Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBITDA too high?
Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-EBITDA is 104.03. The Biotechnology industry median EV-to-EBITDA is 13.91. Biocytogen Pharmaceuticals (Beijing) Co's value of 104.03 is 647.9% above this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #371 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #371 out of 402 companies for EV-to-EBITDA. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.91. Biocytogen Pharmaceuticals (Beijing) Co's value of 104.03 is 647.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.91, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-EBITDA of 104.03 is 647.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biocytogen Pharmaceuticals (Beijing) Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current EV-to-EBITDA is 104.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.14, compared to a current price of €6.30 — trading 100.6% above its estimated fair value. The current EV-to-EBITDA is 104.03 and 647.9% above the Biotechnology industry median of 13.91. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current EV-to-EBITDA is 104.03 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued.
The current stock price of €6.30 is trading 100.6% above its estimated GF Value™ of €3.14.
GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.
Key valuation signals for FRA:I54:
EV-to-EBITDA: 104.03
GF Value™: €3.14 vs. price of €6.30 (100.6% above fair value)
Industry Position: 647.9% above the Biotechnology median (#371 of 402)
No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
72GF Score
Get the complete analysis for FRA:I54
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:I54 has been successfully added to your 
